Waterdrop Launches Insurance against Breast Cancer Recurrence
BEIJING, Nov. 4, 2022 /PRNewswire/ -- The National Cancer Institute(NCI)'s SEER statistics show that breast cancer recurrence rate is as much as 30%. According to the 2022 White Paper on the Quality of Life of Breast Cancer Patients in China, more than 70% of breast cancer patients are worried about recurrence. For these people, Waterdrop launched insurance against...
Waterdrop Wins the NBD “Annual Insurtech Progress Award”
BEIJING, Nov. 4, 2022 /PRNewswire/ -- At the recent 2022 Summit on China's Financial Development and the 13th China Jinding (Finance) Awards organized by the National Business Daily(NBD), a nationwide Chinese financial and economic daily newspaper published in Mainland China, Waterdrop won the"Annual Insurtech Progress Award" for its outstanding performance recognized across the industry. As a leading technology platform dedicated...
Certa Therapeutics’ investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases
Research presented today by University of Michigan Medical School highlights FT011's ground-breaking treatment potential from human expression profiles in chronic kidney disease study supported by animal model data The research demonstrated that treatment with FT011 results in a remarkable reversal in the activation of genetic markers associated with fibrosis Fibrosis is responsible for 45 percent of all deaths...
Roche introduces the navify brand for its digital health solutions at HLTH 2022
Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions. The navify portfolio uses digital solutions, analytics and data science to provide insights that address today's real-world challenges in health, enabling confident decisions and leading towards delivery of personalised healthcare. The navify digital solutions reinforce Roche's commitment to help...
NSW Health & Cicada Innovations celebrate Australia’s biggest health startup training program with 1.1k participants in first year
SYDNEY, Nov. 4, 2022 /PRNewswire/ -- The NSW Health Commercialisation Training Program (CT Program), delivered by Australia's pioneer deep tech incubator Cicada Innovations and launched one year ago, hosted a Demo Day on 3rd November 2022 held at Cicada Innovations and attended by NSW Secretary of Health Susan Pearce. Cicada Innovations CEO Sally-Ann Williams The CT Program...
LUMC to Fund New Clinical Trial of Cynata’s Cymerus™ MSCs in Kidney Transplantation
Key Highlights: Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlands, in a new clinical trial in patients who have received a kidney transplant Trial to be funded by LUMC; Cynata will supply iPSC-derived Cymerus mesenchymal stem cells (MSCs) at its cost to facilitate the trial and has full commercial rights There are approximately...
Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC
HONG KONG, Nov. 4, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") announced the patient enrollment completion for the Phase III clinical trial of Ivonescimab (PD-1/VEGF bi-specific antibody, AK112) combined with chemotherapy for the treatment of EGFR-mutant locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) who have failed to epidermal growth...
ASH 2022 | Ascentage Pharma to Present Initial Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Combination with BTK Inhibitors for the Treatment of R/R CLL/SLL, Including an ORR of...
SUZHOU, China, and ROCKVILLE, Md., Nov. 4, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the initial results from a global Phase II study of the company's Bcl-2-selective inhibitor, lisaftoclax (APG-2575), as a monotherapy...
ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting
SUZHOU, China, and ROCKVILLE, Md., Nov. 4, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the updated results from three studies of the company's novel drug candidate, olverembatinib (HQP1351), have been selected for oral...
Werfen to Acquire Immucor, Inc., Expanding its Presence in Specialized Diagnostics
Werfen enters into an agreement to acquire Immucor, Inc., a privately held, US-based corporation, with a solid global presence in transfusion and transplant in vitro diagnostics The transaction is expected to close during the first half of 2023 BARCELONA, Spain, Nov. 4, 2022 /PRNewswire/ -- Werfen announced today that...
